MENACTRA 4.0 MCG / 0.5 ML — DIN 02279924
MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP Y : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP A : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP C : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP W 135 : 4.0 MCG / 0.5 ML · SANOFI PASTEUR LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is MENACTRA?
MENACTRA 4.0 MCG / 0.5 ML contains MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP Y : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP A : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP C : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP W 135 : 4.0 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02279924, held by SANOFI PASTEUR LIMITED, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 19-Dec-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is MENACTRA used for?
Menactra® is indicated for active immunization for the prevention of invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y and W-135 in persons 9 months through 55 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated cost around the world?
Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 3 | 3 | CZK███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
4 pack listings across 4 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated, across 3 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI PASTEUR LIMITED | 2 | 1 | MENACTRA, MENQUADFI | Sourceable in Canada |
| GLAXOSMITHKLINE INC | 1 | 1 | MENVEO | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 4.0 MCG / 0.5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated |
|---|---|
| ATC code | J07AH08 |
| AHFS class | 80:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02279924 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2279924 |
| Brand name | MENACTRA |
| Generic / active ingredient | MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP Y : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP A : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP C : 4.0 MCG / 0.5 ML MENINGOCOCCAL POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE, GROUP W 135 : 4.0 MCG / 0.5 ML |
| Market authorization holder | SANOFI PASTEUR LIMITED |
| Health Canada schedule | Schedule D |
| ATC code | J07AH08 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07AH |
| Current status | CANCELLED POST MARKET |
| Status date | 19-Dec-2025 |
| Original market date | 2006-10-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MENQUADFI | 55 MCG / 0.5 ML | SOLUTION | SANOFI PASTEUR LIMITED | MARKETED | 02507161 |
| MENVEO | 47 MCG / 0.5 ML | POWDER FOR SOLUTION ; SOLUTION | GLAXOSMITHKLINE INC | MARKETED | 02347393 |
2 · Same class — other molecules in ATC J07AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated | MENACTRA · MENQUADFI · MENVEO | 3 | 2 | Yes |
| Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen | MENOMUNE-A/C/Y/W-135 · NIMENRIX | 4 | 1 | Yes |
| Meningococcal Vaccines | MENJUGATE · MENJUGATE LIQUID · TRUMENBA | 3 | 1 | Yes |
| Meningococcus C, Purified Polysaccharides Antigen Conjugated | MENINGITEC · NEISVAC-C | 2 | 1 | Yes |
| Meningococcus B, Multicomponent Vaccine | BEXSERO | 1 | 1 | Yes |
| Meningococcus, A, C, Bivalent Purified Polysacc. Antigen | MENCEVAX AC PWS 500MCG/VIAL · MENCEVAX AC PWS 50MCG/VIAL · MENCEVAX AC PWS INJ 2500MCG/VIAL · MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUPS A & C | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07AL | Pneumococcus, Purified Polysacc.antigen Conjugated · Pneumococcus, Purified Polysaccharides Antigen | 11 | 3 |
| J07AE | Cholera, Inactivated, Whole Cell · Cholera, Live Attenuated | 4 | 2 |
| J07AP | Typhoid, Inactivated, Whole Cell · Typhoid, Oral, Live Attenuated · Typhoid, Purified Polysaccharide Antigen | 5 | 2 |
| J07AJ | Pertussis, Inact., Whole Cell, Comb. With Toxoids · Pertussis, Inactivated, Whole Cell · Pertussis, Purified Antigen · Pertussis, Purified Antigen, Comb. With Toxoids | 7 | 1 |
| J07AM | Tetanus Toxoid · Tetanus Toxoid, Comb. With Diphtheria Toxoid | 7 | 1 |
| J07AX | Other Bacterial Vaccines | 4 | 1 |
| J07AG | Hemophilus Influenzae B Vaccines · Hemophilus Influenzae B, Combinations With Pertussis And Toxoids · Hemophilus Influenzae B, Combinations With Toxoids · Hemophilus Influenzae B, Purified Antig. Conjugated | 8 | 1 |
| J07AF | Diphtheria Toxoid | 4 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL | PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02240255 |
| DUKORAL | VIBRIO CHOLERAE INABA 48 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE INABA 6973 EL TOR BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS RECOMBINANT CHOLERA TOXIN B SUBUNIT : 1 MG | VALNEVA SWEDEN AB | MARKETED | 02247208 |
| VAXCHORA | VIBRIO CHOLERAE, STRAIN CVD 103-HGR, LIVE : 2000000000 UNIT | BAVARIAN NORDIC AS | MARKETED | 02538164 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MENACTRA called?
The same molecule, Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen Conjugated, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| MENQUADFI | Latin | Czechia, South Africa |
| MENVEO | Latin | Czechia |
| NIMENRIX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.